Hybrid GH Secretagogues Combining NN703 and Ipamorelin Features Are Potent In Vitro and In Vivo
Hybrid compounds combining structural elements of the oral GH secretagogue NN703 with ipamorelin's core showed potent GH-releasing activity in cell assays and in live pigs.
Quick Facts
What This Study Found
NN703-ipamorelin hybrid GH secretagogues showed low nanomolar in vitro potency in pituitary cell assays and effective GH release in pigs in vivo, validating the hybrid design approach.
Key Numbers
How They Did This
In-vitro pituitary cell assay (rat) and in-vivo single-dose GH release testing in pigs for a series of NN703-ipamorelin hybrid compounds.
Why This Research Matters
Creating more potent oral GH secretagogues is key to developing practical GH deficiency treatments. Combining proven scaffolds is an efficient drug design strategy.
The Bigger Picture
Drug design by combining successful structural elements from different compounds is a proven pharmaceutical strategy. These hybrids represent the ongoing optimization of oral GH secretagogues.
What This Study Doesn't Tell Us
Short abstract with limited pharmacological detail. Single-dose pig study. Oral bioavailability not confirmed for all hybrids.
Questions This Raises
- ?Do the most potent hybrids maintain ipamorelin's selectivity?
- ?Can these achieve oral bioavailability suitable for clinical use?
- ?How do they compare to MK-677 for clinical development?
Trust & Context
- Key Stat:
- Nanomolar + in vivo Hybrid compounds achieved low nanomolar cell potency AND effective GH release in pigs — both benchmarks needed for drug development
- Evidence Grade:
- Preliminary evidence with both in vitro and in vivo validation, though limited by brief reporting and single-dose animal testing.
- Study Age:
- Published in 2001. NN703 entered clinical trials; the hybrid optimization approach continues to inform GH secretagogue drug design.
- Original Title:
- Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin.
- Published In:
- Bioorganic & medicinal chemistry letters, 11(14), 1915-8 (2001)
- Authors:
- Hansen, T K(2), Ankersen, M(4), Raun, K(3), Hansen, B S
- Database ID:
- RPEP-00666
Evidence Hierarchy
Frequently Asked Questions
Why combine two existing peptides?
NN703 has oral activity (it can be taken as a pill) while ipamorelin has excellent selectivity (only releases GH). Combining their best features creates compounds with both advantages — oral and selective.
Are these available to use?
Not yet. These are early-stage research compounds being tested for drug development potential. They represent the ongoing optimization work needed before a new drug reaches patients.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00666APA
Hansen, T K; Ankersen, M; Raun, K; Hansen, B S. (2001). Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin.. Bioorganic & medicinal chemistry letters, 11(14), 1915-8.
MLA
Hansen, T K, et al. "Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin.." Bioorganic & medicinal chemistry letters, 2001.
RethinkPeptides
RethinkPeptides Research Database. "Highly potent growth hormone secretagogues: hybrids of NN703..." RPEP-00666. Retrieved from https://rethinkpeptides.com/research/hansen-2001-highly-potent-growth-hormone
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.